RU2006140384A - Способ модулирования васкуляризации - Google Patents

Способ модулирования васкуляризации Download PDF

Info

Publication number
RU2006140384A
RU2006140384A RU2006140384/14A RU2006140384A RU2006140384A RU 2006140384 A RU2006140384 A RU 2006140384A RU 2006140384/14 A RU2006140384/14 A RU 2006140384/14A RU 2006140384 A RU2006140384 A RU 2006140384A RU 2006140384 A RU2006140384 A RU 2006140384A
Authority
RU
Russia
Prior art keywords
signaling pathway
par
inhibitor
viia
factor
Prior art date
Application number
RU2006140384/14A
Other languages
English (en)
Other versions
RU2378006C2 (ru
Inventor
Мартин ФРИДЛЭНДЕР (US)
Мартин Фридлэндер
Вольфрам РУФ (US)
Вольфрам РУФ
Майкл ДОРРЕЛЛ (US)
Майкл ДОРРЕЛЛ
Маттиас БЕЛТИНГ (SE)
Маттиас БЕЛТИНГ
Original Assignee
Дзе Скриппс Рисерч Инститьют (Us)
Дзе Скриппс Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Скриппс Рисерч Инститьют (Us), Дзе Скриппс Рисерч Инститьют filed Critical Дзе Скриппс Рисерч Инститьют (Us)
Publication of RU2006140384A publication Critical patent/RU2006140384A/ru
Application granted granted Critical
Publication of RU2378006C2 publication Critical patent/RU2378006C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (12)

1. Способ модулирования васкуляризации в тканях млекопитающих, который включает управление сигнальным путем рецептора, активируемого протеазами (PAR), в указанных тканях.
2. Способ по п.1, где управление включает ингибирование PAR-2 сигнального пути.
3. Способ по п.1, где контроль включает ингибирование PAR-1 сигнального пути.
4. Способ по п.1, где сигнальный путь PAR управляется с помощью регулирования фосфорилирования цитоплазматического домена тканевого фактора в указанной ткани.
5. Способ по п.1, где сигнальный путь PAR управляется введением млекопитающим, страдающим от патологической неоваскуляризации, эффективных количеств ингибитора сигнального пути PAR.
6. Способ по п.5, где ингибитором сигнального пути PAR является ингибитор активации TF- VIIa.
7. Способ по п.6, где ингибитор сигнального пути TF-VIIa выбран из группы, включающей активный центр ингибированного фактора VIIa (VIIai), антикоагулянтный пептид с2 нематод (NAPc2), антитело, специфичное к фактору VIIa, антитело, специфичное к комплексу тканевой фактор - фактор VIIa (комплекс TF-VIIa), и их комбинаций.
8. Способ по п.5, где ингибитором сигнального пути PAR, является ингибитор передачи сигнала β-рецептора PDGF.
9. Способ по п.8, где ингибитором передачи сигнала β-рецептора PDGF является антитело, специфичное к PDGF-ВВ.
10. Способ по п.3, где ингибитором сигнального пути PAR является ингибитор фосфорилирования цитоплазматического домена тканевого фактора.
11. Способ по п.5, где заболеванием является рак, включающий прогрессирование опухоли, или ишемическое ретинопатическое заболевание.
12. Способ по п.1, где млекопитающим является человек.
RU2006140384/14A 2004-04-16 2005-04-15 Способ модулирования васкуляризации RU2378006C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56282104P 2004-04-16 2004-04-16
US60/562,821 2004-04-16

Publications (2)

Publication Number Publication Date
RU2006140384A true RU2006140384A (ru) 2008-05-27
RU2378006C2 RU2378006C2 (ru) 2010-01-10

Family

ID=36090415

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006140384/14A RU2378006C2 (ru) 2004-04-16 2005-04-15 Способ модулирования васкуляризации

Country Status (12)

Country Link
US (1) US20070207154A1 (ru)
EP (1) EP1735011A4 (ru)
JP (1) JP2007532668A (ru)
KR (1) KR20070012715A (ru)
CN (1) CN101115494A (ru)
AU (1) AU2005287449A1 (ru)
BR (1) BRPI0509776A (ru)
CA (1) CA2563304A1 (ru)
MX (1) MXPA06011952A (ru)
RU (1) RU2378006C2 (ru)
WO (1) WO2006033669A2 (ru)
ZA (1) ZA200608490B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
CN101870974A (zh) * 2010-05-26 2010-10-27 中国科学院昆明动物研究所 蛋白酶激活受体激动剂的制备方法及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
JP2001510168A (ja) * 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ ＦＶＩＩａ媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのＦＶＩＩａ又はＦＶＩＩａｉの使用
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
AU5807500A (en) * 1999-07-14 2001-02-05 Novo Nordisk A/S Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
ITRM20010088A1 (it) * 2001-02-21 2002-08-21 Idi Irccs Peptide in grado di inibire l'attivita' del fattore di crescita derivato dalle piastrine (pdgf-bb) e del fattore di crescita derivato dai fi
US20050232925A1 (en) * 2002-03-18 2005-10-20 Sukhatme Vikas P Protease activity of thrombin inhibits angiogenesis
US20040072755A1 (en) * 2002-07-12 2004-04-15 Stennicke Henning Ralf TF antagonist
CA2527621A1 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies

Also Published As

Publication number Publication date
KR20070012715A (ko) 2007-01-26
CA2563304A1 (en) 2006-03-30
WO2006033669A2 (en) 2006-03-30
JP2007532668A (ja) 2007-11-15
CN101115494A (zh) 2008-01-30
RU2378006C2 (ru) 2010-01-10
EP1735011A4 (en) 2008-03-26
MXPA06011952A (es) 2007-01-16
US20070207154A1 (en) 2007-09-06
AU2005287449A1 (en) 2006-03-30
EP1735011A2 (en) 2006-12-27
BRPI0509776A (pt) 2007-10-23
ZA200608490B (en) 2008-08-27
WO2006033669A3 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
US7276050B2 (en) Trans-scleral drug delivery method and apparatus
Delacroix et al. Cochlear afferent innervation development
EA029485B1 (ru) Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
Seiwerth et al. Stable gastric pentadecapeptide BPC 157 and wound healing
EA029085B1 (ru) Способ лечения иммуноопосредуемых и воспалительных заболеваний с помощью 3-[4-(4-морфолин-4-илметилбензилокси)-1-оксо-1,3-дигидроизоиндол-2-ил]пиперидин-2,6-диона
Sangawa et al. Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart
RU2006140384A (ru) Способ модулирования васкуляризации
Sharma et al. Surgical modifications, additions, and alternatives to Kasai hepato-portoenterostomy to improve the outcome in biliary atresia
Påhlman et al. Pre‐operative and post‐operative radiotherapy and rectal cancer
Chan et al. Effect of side and size of graft on surgical outcomes of adult‐to‐adult live donor liver transplantation
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
JP2015227338A (ja) 虚血／卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
JP2002542297A (ja) 血管形成を増強するための治療組成物および方法
Todurov et al. Usefulness of applying temporary intracoronary shunts for myocardial revascularization
Klinge et al. Absence of circulating aldosterone attenuates foreign body reaction around surgical sutures
Gavras et al. Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure
Garner Unrecognized Participation of the Lymphatic System in Medication Side Effects and Development of Salt-Sensitive Hypertension
Lei et al. A4490 Effects of esaxerenone (CS-3150), a non-steroidal selective of mineralocorticoid receptor antagonist, on blood pressure and renal injury in Dahl salt-sensitive rats
Kim et al. Molecular mechanisms in keloid biology
Honkanen METHODS OF SPINAL CORD PROTECTION IN AORTIC SURGERY
Talbot et al. Connexin43 and development of primary bone tumors: osteosarcoma and Ewing's sarcoma
Bergdahl et al. Altered neuropeptide Y Y1 responses in mesenteric arteries in rats with congestive heart failure
Juan et al. A6695 Effects of high sodium on the proliferation and phenotype transformation of rat cardiac fibroblasts cells
Modder et al. Pathophysiology of erectile dysfunction following radical prostatectomy
RU2537768C2 (ru) Способ ортотопической трансплантации трупной печени

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110416